40.6K
Downloads
118
Episodes
Equity.Guru's Chris Parry and his expert journalism team talk to business leaders, executives and investors about opportunities in North America and beyond.
Episodes
Friday Dec 04, 2020
Friday Dec 04, 2020
Welcome once again to Equity Guru’s Short and Sweet where we distill our in-depth interviews into solid nuggets of gold, enabling you to drink down the cream of each conversation in one delectable 5-minute gulp. In this week’s three-part episode, we are drawing from The Jody Vance Experience where Jody speaks with Brigadier Gold (BRG.V) president, CEO and director, Ranjeet Sundher, PredictMedix (PMED.C) CEO, Dr. Rahul Kushwah and EarthRenew (ERTH.C) CEO and director, Keith Driver. Listen in!
Full disclosure: Brigadier Gold, PredictMedix and EarthRenew are Equity.Guru marketing clients.
Monday Nov 23, 2020
Monday Nov 23, 2020
Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.
Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors.
Here are the highlights!
Monday Nov 23, 2020
Monday Nov 23, 2020
Welcome to the second installment!
Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.
Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Listen in!
Monday Nov 23, 2020
Monday Nov 23, 2020
Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.
Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Tune in!
Friday Nov 13, 2020
Friday Nov 13, 2020
Time for part 2! Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!
Friday Nov 13, 2020
Friday Nov 13, 2020
Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!
Friday Nov 13, 2020
Friday Nov 13, 2020
This is the final segment where Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!
Friday Nov 13, 2020
Friday Nov 13, 2020
It's not all about legal cannabis anymore, Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!
Wednesday Oct 28, 2020
Wednesday Oct 28, 2020
Ahead of Kwesst's initial public offering (IPO), Equity Guru's own Chris Parry talks with the company's Executive Chairman David E. Luxton to gives us a closer look into what the company does and where they're headed.
Thursday Jun 18, 2020
Thursday Jun 18, 2020
KWESST is a Canadian military tech company that is “making dumb weapons smart” by developing proprietary technology for the military and homeland security markets.
The total Global Defense Budget is estimated at USD $1.8 Trillion in 2020 and the market is expected to grow to USD $2.3 Trillion by 2028.
“Thirteen conflicts are identified as top priorities for the United States,” states The Council on Foreign relations.
KWESST has a diversified product line, based on a single core technology, called Micro Integrated Sensor Systems Technology (MISST), which involves miniaturized sensors, optics, ballistics and software which claims to significantly jack-up mission capability.
In this pt. 2 podcast, Equity Guru’s Guy Bennett talks to David Luxton, Executive Chairman of KWESST about laser warfare, shot counters, the management team, global markets, 2020 objectives, share structure and KWESST’s “Blue Sky Story”.
Full Disclosure: KWESST is an Equity Guru marketing client.